In a phase II study of 6-12 months of adefovir dipivoxil treatment in human immunodeficiency virus (HIV)-infected patients, HIV from 8 of 29 patients developed mutations in reverse transcriptase (RT) potentially attributable to adefovir dipivoxil therapy. Recombinant HIV from pre-and posttreatment plasma samples from these 8 patients showed no change or minor decreases in adefovir susceptibility, consistent with the durable antiviral effect observed. Additionally, HIV from 8 patients developed the M184V RT mutation because of concomitant lamivudine use. Recombinant HIV pairs from all 4 patients with zidovudineresistant HIV showed statistically significant increases in adefovir susceptibility of 3-to 4-fold (to near wild type IC 50 ), and HIV pairs from 2 of 4 patients with zidovudine-sensitive HIV showed a 2-to 3-fold increase in susceptibility. In growth kinetics studies, expression of the M184V RT mutation resulted in attenuated viral growth in peripheral blood mononuclear cell cultures. These studies suggest that patients possessing HIV with zidovudine and lamivudine resistance mutations may benefit from adefovir dipivoxil therapy.
In a phase II study of 6-12 months of adefovir dipivoxil treatment in human immunodeficiency virus (HIV)-infected patients, HIV from 8 of 29 patients developed mutations in reverse transcriptase (RT) potentially attributable to adefovir dipivoxil therapy. Recombinant HIV from pre-and posttreatment plasma samples from these 8 patients showed no change or minor decreases in adefovir susceptibility, consistent with the durable antiviral effect observed. Additionally, HIV from 8 patients developed the M184V RT mutation because of concomitant lamivudine use. Recombinant HIV pairs from all 4 patients with zidovudineresistant HIV showed statistically significant increases in adefovir susceptibility of 3-to 4-fold (to near wild type IC 50 ), and HIV pairs from 2 of 4 patients with zidovudine-sensitive HIV showed a 2-to 3-fold increase in susceptibility. In growth kinetics studies, expression of the M184V RT mutation resulted in attenuated viral growth in peripheral blood mononuclear cell cultures. These studies suggest that patients possessing HIV with zidovudine and lamivudine resistance mutations may benefit from adefovir dipivoxil therapy.
Adefovir (9-[2-phosphonomethoxyethyl]adenine, PMEA) is a member of a new class of nucleotide-based antivirals and is active against multiple retroviruses, including human immunodeficiency virus (HIV) and simian immunodeficiency virus [1] [2] [3] , as well as DNA viruses, including herpesviruses [4, 5] and hepadnaviruses [6] . The orally bioavailable prodrug, adefovir dipivoxil (bis-POM-PMEA, Preveon; Gilead Sciences, Foster City, CA), has shown activity in phase I/II clinical trials against HIV [7] and is currently in phase III clinical trials for the treatment of HIV disease. Adefovir requires only two phosphorylation steps by ubiquitous cellular enzymes to become the active metabolite, adefovir diphosphate [8, 9] . This novel phosphorylation requirement permits its activity in a wide variety of cell types, including resting T cells and cells of the monocyte/ macrophage lineage [10, 11] . Adefovir diphosphate acts as a competitive inhibitor of reverse transcriptase (RT) with respect to dATP and functions as a chain terminator of viral DNA synthesis [12] .
To address the potential development of resistance to adefovir dipivoxil in vivo, HIV from plasma samples from patients enrolled in a phase I/II trial (GS-94-403) were genetically char-acterized [13] . In this study, 29 patients received 6-12 months of adefovir dipivoxil maintenance therapy, during which concomitant antiretrovirals were permitted. Eight of these 29 patients developed mutations in HIV RT that were not apparent at baseline nor attributable to concomitant medications and, therefore, were potentially attributable to adefovir dipivoxil therapy. All 8 patients, however, continued to show virus load suppression during the study that was of similar magnitude to that seen in patients not developing HIV RT mutations [13] . The current work shows the complete drug susceptibility analyses of pre-and posttreatment recombinant viruses derived from the plasma HIV of these 8 patients.
Since concomitant antiretrovirals were permitted during the extended phase of study GS-94-403, several patients developed the M184V mutation in HIV RT because of the concomitant use of lamivudine. Recombinant HIVs from these patients were also constructed and analyzed for drug susceptibilities in vitro. Previous work has shown that in some cases, the development of the M184V RT mutation results in an increased in vitro susceptibility to zidovudine [14, 15] . In the present work, we sought to corroborate the observations of increased zidovudine susceptibility and investigated effects of the M184V RT mutation on in vitro susceptibility of HIV to both adefovir and a related nucleotide analogue under development, PMPA (9-[2-phosphonomethoxypropyl]adenine). Additionally, numerous patient-derived recombinant viruses were analyzed for their replication capacity in vitro.
Materials and Methods

Patients.
Detailed descriptions of the initial monotherapy phase of study GS-94-403, including study design and clinical reDownloaded from https://academic.oup.com/jid/article-abstract/179/1/92/885064 by guest on 17 March 2019 sults, have been reported [7] . After patients completed the initial phase, they were eligible to enroll in a 6-to 12-month maintenance dosing phase in which concomitant antiretrovirals were permitted. Genotypic analysis of HIV RT from pre-and posttreatment plasma virus was done for the 29 patients who completed 6-12 months of therapy as previously described [13] .
Recombinant HIV production. Polymerase chain reaction (PCR) fragments corresponding to the first 1 kb of HIV RT were generated from patient plasma samples obtained at baseline and after either 6 months or 12 months of adefovir dipivoxil therapy as previously described [13] . Four micrograms of the PCR fragments was cotransfected with 6 mg of the RT-deleted HIV-1 proviral molecular clone pHXB2D2-261RT (gift of C. Boucher) as described by Boucher et al. [16] . Replication-competent viruses generated by homologous recombination were harvested when the cultures contained notable syncytia, 8-18 days later. The genotypes of the recombinant viruses were determined by RT-PCR of 140 mL of DNase-treated virus supernatant and subsequent sequencing with single dye-labeled overlapping primers on both strands of DNA with an automated DNA sequencer (ALF Express; Pharmacia, Piscataway, NJ). The sequence of the resultant RT recombinant viruses corresponded to the RT sequence of the respective patient's plasma HIV at 197% of the 900 bases sequenced.
Antiviral drug susceptibility assays. Susceptibility of the recombinant viruses to adefovir, PMPA, zidovudine, abacavir, zalcitabine, lamivudine, stavudine, didanosine, and ritonavir was evaluated by a modified XTT-based assay in MT-2 cells as previously described [13, 17] . For comparison, the wild type HIV-1 molecular clone HXB2D and the site-directed K70E RT mutant [17] were also evaluated. All infections were done at an MOI of ∼0.001, which resulted in equal levels of cell killing in the absence of drug over the 5-day assay period. IC 50 s were calculated as an average of 3-6 experiments, and statistical significance was evaluated between pre-and posttreatment IC 50 values by the two-tailed Student's t test.
HIV replication kinetics analyses. Peripheral blood mononuclear cells (PBMC) from HIV-negative blood donors were isolated by density centrifugation, activated with 5 mg/mL phytohemagglutinin-P (Sigma, St. Louis) for 2 days, frozen, thawed, and then expanded in RPMI with 20% fetal bovine serum (Irvine Scientific, Santa Ana, CA) and 20 U/mL recombinant human interleukin-2 (Boehringer Mannheim, Indianapolis). After a total of 6 days in culture, cells were infected with recombinant HIV at an 6 1.2 ϫ 10 MOI of ∼0.001. The HIV was previously titered by limiting dilution in MT-2 cells to obtain a TCID 50 value, and titration values were adjusted, if necessary, to result in equivalent 5-day MT-2 cell killing (based on drug susceptibility testing described above). Eighteen hours later, the cells were washed three times with PBS and then recultured in interleukin-2-containing RPMI for 3 weeks. No additional PBMC were added to the cultures. Supernatant samples were removed every 3-4 days during media exchanges and evaluated for p24 concentration by ELISA (Coulter-Immunotech, Westbrook, ME).
Results
Antiviral drug susceptibility analyses of HIV from patients developing mutations in RT potentially associated with adefovir
dipivoxil. As previously published [13] , HIV from 8 of 29 patients who completed 6-12 months of adefovir dipivoxil treatment developed mutations in RT that were not attributable to their concomitant medications (table 1). Two patients developed a K70E mutation (patients A, G), 2 patients developed a T69D mutation (patients E, F), and 4 patients developed hallmark zidovudine resistance mutations (patients B, C, D, H) in their HIV. The development of the K70E mutation was expected from previous in vitro selection experiments [17] . The T69D mutation has been previously observed to arise in HIV RT as a result of zalcitabine therapy [18] . The development of zidovudine resistance mutations in these patients who were not taking zidovudine was unexpected but has also been shown to occur during didanosine or stavudine monotherapy [19] [20] [21] . In all 8 patients, however, virus load suppression was maintained despite the development of these mutations [13] . To further understand the basis of these clinical results, recombinant viruses were constructed by homologous recombination of the RT sequence from both pre-and posttreatment plasma HIV samples into an RT-deleted molecular clone. Antiviral drug susceptibility assays were done with all approved nucleoside RT inhibitors, adefovir, PMPA, and abacavir (table 1) . A protease inhibitor, ritonavir, was included as an internal control in these experiments, since all of these recombinant viruses are genetically identical in the protease gene. In 7 of the 8 cases, changes in susceptibility to adefovir among the pre-and posttherapy viruses were !3-fold, consistent with the continued virus load suppression observed in vivo. HIV from patient D, however, showed a 9-fold decrease in adefovir susceptibility. This patient, as opposed to the other 7, developed his HIV RT mutations at the final time point of study (12 months), and thus the subsequent effects of these mutations in vivo were not ascertained.
With regard to PMPA susceptibilities among these 8 virus pairs, only HIV from patient D showed a minor decrease in PMPA susceptibility and at the same time also showed decreased susceptibility to zidovudine, abacavir, stavudine, and lamivudine. As expected, viruses that developed zidovudine resistance mutations (from patients B, C, D, H) showed notable decreases in zidovudine susceptibility. Viruses from patients F and G, whose HIV also developed the M184V mutation because of their concomitant lamivudine use, showed dramatic decreases in lamivudine susceptibility as well as 4-to 11-fold decreases in abacavir susceptibility. Posttherapy HIV from patient F also showed an increase in zidovudine susceptibility, as has been previously shown for some patients with high-level zidovudine-resistant viruses who develop lamivudine resistance [14, 15] . Surprisingly, HIV from patient F also demonstrated an increase in adefovir and PMPA sensitivities, of 2.6-fold ( ) and 1.9-fold ( ), respectively. With respect to P ϭ .01 P ϭ .28 zalcitabine and didanosine susceptibilities among these 8 virus pairs, only the posttherapy virus from patient G showed changes in susceptibility, demonstrating a decrease in didano- sine and zalcitabine susceptibility of 2.4-fold and 3.6-fold, respectively (data not shown).
Antiviral drug susceptibility analyses of HIV from patients developing the lamivudine-associated M184V mutation in RT.
To further address the increased adefovir and PMPA susceptibility observed with HIV from patient F, additional recombinant viruses were constructed from other patients developing the M184V RT mutation because of concomitant lamivudine use. Three additional patients (patients I, J, K), like patient F, entered the study with high-level zidovudine-resistant HIV conferred by multiple mutations within RT. Viruses from these patients showed the same phenotypic pattern of drug susceptibilities on development of the M184V mutation as was observed with viruses from patient F: increased susceptibility to adefovir, PMPA, and zidovudine and decreased susceptibility to lamivudine and abacivir (table 2). The increase in adefovir susceptibility for posttreatment HIV from each of the 4 patients was statistically significant ( ) compared with their pre-P ! .03 treatment HIV strain. The average posttreatment zidovudine IC 50 in viruses from these 4 patients was 1.0 mM, still 4-fold above that of the wild type HXB2D recombinant, whereas the average posttreatment adefovir IC 50 was 22.8 mM, only 1.5-fold above that of the HXB2D wild type. In terms of individual patients, posttreatment HIV from 3 of these 4 patients were still 13-fold resistant to zidovudine, whereas viruses from all 4 patients were within 2-fold of the wild type adefovir IC 50 . Similarly, posttreatment viruses from all 4 patients were within 2-fold of wild type PMPA IC 50 s. Thus, the development of the M184V mutation in zidovudine-resistant viruses consistently results in increased drug susceptibility for both adefovir and PMPA, to within 2-fold of wild type IC 50 s of these drugs. With respect to zalcitabine and didanosine susceptibilities among these 4 virus pairs, posttreatment virus from patient J showed a 2.6-fold decrease in didanosine susceptibility.
The capacity of the M184V mutation to increase the in vitro susceptibility to adefovir and PMPA was also evaluated in recombinant viruses derived from patients lacking high-level zidovudine resistance mutations in their HIV RT (table 3) . HIV from patient E developed T69D at 6 months and later developed the M184V mutation at 12 months because of concomitant lamivudine use. Patient L's HIV RT developed M184V in the absence of any other known nucleoside RT inhibitor mutations, whereas HIV from patient M developed the M184V and K70R RT mutations simultaneously. In the final patient (patient N), the M184V mutation became undetectable in the plasma because of the cessation of lamivudine therapy during study. Viruses expressing the M184V RT mutation from patients E and N showed 2-to 3-fold increases in adefovir sus- ceptibility, while viruses from patients L and M showed no change. Thus, in the absence of high-level zidovudine resistance mutations, the development of the M184V mutation results in moderate increases in adefovir susceptibility in the HIV from 2 of 4 patients, although these differences do not achieve statistical significance ( ). With respect to zidovudine, viruses P 1 .05 from patients E, L, and N became highly susceptible to zidovudine, while HIV from patient M showed no change in zidovudine susceptibility. In all 4 of these cases, the presence of the M184V mutation decreased 1592U89 susceptibilities from 2-to 5-fold. There were no notable changes in didanosine susceptibilities among viruses from these patients, whereas consistent 2-to 3-fold decreases in zalcitabine susceptibility were observed, as expected due to cross-resistance of the M184V mutation with zalcitabine [22] .
Replication kinetics studies. Previous studies have shown that site-directed HIV recombinants expressing either the K70E [17] or the M184V [23] mutations in RT confer decreased replication capacity in vitro. We have extended these studies to include 8 pairs of homologous recombinant viruses expressing a variety of patient-derived genetic backgrounds in RT. All viruses were rigorously normalized for infection equivalence and then grown in activated primary PBMC cultures for 21 days. As shown in figure 1A , virus from patient A expressing the K70E mutation showed decreased replication in vitro, in agreement with our previous observations using a K70E sitedirected recombinant [17] . HIV from patients G, L, E, J, and K ( figure 1B-1F ) all developed the M184V mutation, either alone or along with other nucleoside RT inhibitor resistance mutations. In all of these cases, there were modest to marked decreases in the replication capacity of viruses expressing the M184V mutation in the primary PBMC cultures. Posttreatment HIV from patient G developed both the K70E and M184V mutations simultaneously, and this resulted in strongly compromised in vitro growth (figure 1B). HIV from patient E first developed the T69D mutation but then additionally developed the M184V mutation at 12 months, also resulting in strongly compromised in vitro growth ( figure 1D ). All patients whose HIV RT developed the M184V mutation in the presence of high-level zidovudine resistance (patients F, I, J, K) showed decreased HIV replication in their posttreatment virus (figure 1E, 1F; data not shown). In contrast, experiments using preand posttreatment matched pairs of homologous recombinant viruses from patients C and D, who developed high-level zidovudine resistance mutations in HIV RT in the absence of the M184V mutation, showed no difference in replication capacity in vitro ( figure 1G, 1H) . Thus, the presence of the M184V or K70E mutations can specifically decrease the replication capability of HIV in a variety of patient-derived RT genetic backgrounds of HIV, including those expressing high-level zidovudine resistance mutations.
Discussion
The use of combination antiretroviral therapy for the treatment of HIV disease has resulted in dramatically reduced virus loads and improved health for many HIV-infected people. However, the capability of therapies to select for resistant HIV and potentially reduce therapeutic efficacy is well-established [24] . In many patients, the use of multiple antiretroviral drugs under conditions that do not completely suppress viral replication results in complex genetic resistance patterns in the RT and protease genes. Interactions between mutations in either of these enzymes often results in increased resistance and broadened cross-resistance [25, 26] . On the other hand, some mutational interactions may have favorable effects. The development of the M184V mutation because of lamivudine treatment can result in an increase in zidovudine susceptibility for highly zidovudine-resistant HIV containing the T215Y mutation in RT [14, 15, 27] . These in vitro findings correlate with and may contribute to the more durable clinical responses observed in patients undergoing combination therapy with zidovudine and lamivudine compared with those undergoing individual monotherapies, in spite of the development of lamivudine resistance [27] [28] [29] . Increases in zidovudine susceptibility have also been observed with the addition of the didanosine-associated L74V and the nonnucleoside RT inhibitor-associated Y181C mutations in RT [15, 30, 31] . However, these mutations are not as commonly observed as the M184V mutation, and the Y181C mutation is specifically suppressed in combination therapy with nevirapine and zidovudine [32] .
In the present studies, we show that the development of the lamivudine-associated M184V RT mutation in paired recombinant HIV isolates increases the in vitro susceptibility for two compounds under clinical development, adefovir and PMPA, while decreasing the in vitro susceptibilities for lamivudine and 1592U89. The clinical significance of these in vitro observations for adefovir is now being determined. Preliminary clinical results in patients adding adefovir dipivoxil to a stable antiretroviral regimen indicate that patients whose HIV expresses the M184V mutation show greater plasma viral RNA reductions than do patients whose HIV is wild type at codon 184 [33] .
Genetic changes in HIV that are selected for by antiretroviral treatment must provide, by definition, some selective advantage for the growth of the mutant virus in the presence of the selecting drug(s). However, the level of drug resistance conferred by the genetic changes may not be sufficient to overcome the inhibitory concentration of the active drug in vivo. Thus, not all genetic changes necessarily result in increasing virus loads. In the current phenotypic analyses of viruses from 8 patients developing mutations in RT potentially associated with adefovir dipivoxil therapy, a range of in vitro drug susceptibility values were obtained for adefovir. The low-level changes in adefovir susceptibility ( !3-fold) observed in HIV from 7 of 8 patients did not result in an increase in virus load in vivo, even though 3 of these patients (patients A-C) were receiving adefovir dipivoxil monotherapy and their HIV genetic changes had been present for 6-9 months during the study [13] . These results suggest that decreases in adefovir susceptibility of !3-fold are not clinically significant. The single patient with HIV that showed a 13-fold decrease in adefovir susceptibility, patient D, was also receiving adefovir dipivoxil monotherapy. Although this patient also showed continued virus load suppression, the HIV RT mutations were only detected as mutant/wild type mixtures at the final virus load time point of the study. Thus, it is not possible to determine the clinical effects of the observed 9-fold decrease in adefovir susceptibility in HIV from this patient.
HIV from all of the patients whose virus developed the M184V mutation in RT because of concomitant lamivudine use showed decreases in susceptibility for abacavir, a nucleoside analogue currently under clinical development. HIV in these 9 patients (patients E-G, I-N) had a variety of genetic backgrounds in RT, including HIV from 4 patients expressing highlevel zidovudine resistance mutations. The magnitudes of these decreases in abacavir susceptibility ranged from 2-to 7-fold among these 9 patients. Previous work has shown a 3-fold decrease in abacavir susceptibility with the addition of the M184V mutation in a site-directed recombinant virus, but greater decreases in abacavir susceptibility required additional mutations in RT, specifically the L74V and K65R mutations [34] . The present work shows larger fold changes without the requirement of these particular additional mutations in recombinant clinical isolates. These results are in agreement with more recent evidence showing that expression of the M184V mutation with multiple nucleoside RT inhibitor-associated mutations results in a greater degree of in vitro resistance to abacavir [35] . Whether viruses from patients harboring the M184V mutation and showing decreased susceptibility to abacavir in vitro are responsive to abacavir treatment in vivo remains to be determined. Given the large number of nucleoside-experienced patients expressing these genotypes, data from ongoing clinical trials should address this question.
Mutations in HIV that are selected for by antiretroviral drug therapy may result in other phenotypic alterations in addition to altered drug susceptibilities. As a consequence, the ability of the virus to replicate may be impaired by the mutations [23, 36] . As observed with protease inhibitor-associated mutations, secondary compensatory mutations may then arise to partially restore the altered viral fitness [37] . The work presented here further establishes that HIV containing the M184V or the K70E mutation in RT replicates less efficiently than does wild type virus in vitro. No additional compensatory mutations have been defined that modify this deficiency. An indication of the potential clinical relevance of these observations is suggested by the lack of complete rebound to baseline viral RNA values in patients whose HIV expresses the M184V mutation, even after up to 12 months of lamivudine monotherapy in the presence of the lamivudine-resistant virus [28, 29, 38] . Moreover, on discontinuation of lamivudine treatment, plasma HIV quickly repopulates to a wild type codon at aa 184. This has been observed in numerous patients, including patient N in this study, who ceased lamivudine treatment at month 6 and possessed a completely wild type codon at RT aa 184 by month 12 (table 3; unpublished data). This rapid repopulation suggests a strong in vivo growth disadvantage for HIV with the M184V RT mutation in the absence of lamivudine and is in contrast to the stability and transmissibility of HIV with other druginduced mutations in RT, most notably the T215Y mutation [39, 40] . Thus, it is possible that actively maintaining the presence of the M184V mutation in HIV RT with continued lamivudine therapy may provide clinical benefit because of the decreased fitness of the mutant virus, even though the chainterminating antiviral activity of lamivudine as an RT inhibitor is decreased.
Current HIV treatment strategies that use combinations of antiretroviral drugs have provided substantial benefit for HIVinfected patients who can tolerate and comply with these treatment regimens and who are naive to previous antiretroviral treatment. However, many patients have accumulated mutations in the RT and protease genes that appear to limit the effectiveness of currently licensed anti-HIV drugs [24] . With regard to RT, the presence of the zidovudine-associated T215Y mutation is significantly correlated with poor clinical responses to numerous subsequent therapies, including those lacking zidovudine [41] [42] [43] . Even in patients whose HIV RT expresses the lamivudine resistance mutation M184V along with zidovudine resistance mutations, continued zidovudine and lamivudine treatment has been shown to result in dual resistance and eventual clinical decline [44, 45] . The in vitro observations presented here show that the addition of the lamivudine-associated M184V RT mutation to zidovudine-resistant HIV results in increased susceptibility of the zidovudine-and lamivudine-resistant HIV to adefovir and PMPA. These results suggest that treatment with adefovir dipivoxil or PMPA may provide clinical benefit to patients who harbor doubly zidovudine-and lamivudine-resistant viruses. Clinical trials in antiretroviral-experienced patients will determine this possibility.
